Bio-gene Technology Ltd. · ASX:BGT
Bio-gene Technology — Investor Presentation (December 2023)
21 slides from Bio-gene Technology's investor presentation, Dec 13, 2023
Slide 1: Developing New Insecticides Derived From Nature
Developing New Insecticides Derived From Nature to Achieve High Impact - Globally Tim Grogan Managing Director & CEO December 2023 Corporate Overview ASX:BGT www.bio-gene.com.au
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an offer or invitation
Slide 3: Bio-Gene is Developing New Insecticides
Bio-Gene is Developing New Insecticides Derived From Nature to Achieve High Impact - Globally Bio-Gene in Summary 1 Two New Actives Bio-Gene is developing two botanically derived active ingredients with novel insecticidal modes of action: • Flavocide® and Qcide® are derived from a specific type of e
Slide 4: Flavocide & Qcide 101
Flavocide® & Qcide® 101 Novel insecticides derived from nature. QCIDE – a botanical insecticide with a new mode of action Qcide is an 100% natural oil extracted from the leaves of a specific cultivar of eucalypt (Gypmie messmate), containing high levels (>80%) of tasmanone. The trees are currently f
Slide 5: Building Bio-Gene's Product Pipeline
Pipeline: Building Bio-Gene’s Product Pipeline A constant process to select the best. Grain Protectant (F8) Crop Protection Assessment: Outdoor Space Spray (F11) Flavocide® Technical: Opportunities Efficacy & safety data Indoor Barrier Spray (F28) Development pathway Labels & Regulatory Flavocide ®
Slide 6: Bio-Gene's Product Pipeline: Formulated products
Bio-Gene’s Product Pipeline Eight programs across Crop Protection, Public Health & Consumer Sectors. Flavocide® (Active constituent) Pre-registration Description Code Sector Target Market Target Species Use Stage Partner Admixture to Lesser grain borer Crop grain (in Rice weevil, Flour beetle Formul
Slide 7: Flavocide Active Constituent Development Path
Flavocide® Active Constituent Development Path Regulatory approval of a formulated product is a two-step process. Development Definition Validation Regulatory Launch stage gate status: (PoC) (R&D) development (market) Active constituent approval End use product approval and product commercialization
Slide 8: Recent Significant Advancements
Recent Significant Advancements Synergy Data (26 April 2023) (27 July 2023) STK (Qcide) (24 July 2023) CDC Vector Control (Ticks) Flavocide Manufacture (30 October 2023) 8
Slide 9: The Mosquito is the World's Deadliest Animal
The Mosquito is “the World’s Deadliest Animal” 1 Responsible for more human deaths than any other creature on earth. 3 • Mosquitos - approximately 3,600 species of small flies comprising the family Culicidae • Life cycle consists of egg, larva, pupa, and adult stages • Adult females have tube-like m
Slide 10: Current Insecticidal Treatments to Control Flying Pests
Current Insecticidal Treatments to Control Flying Pests Rapidly increasing number of countries with resistant mosquitos. Current Insecticidal Treatments Professional & Public Health (Flying pests & vector control) Customers Have Synthetic insecticides (organophosphorus, carbamate, Significant Unmet
Slide 11: Flavocide & Qcide Active Constituents
Flavocide® & Qcide® Active Constituents New mode of action insecticides for flying & crawling insects. Active constituent dossier Target Regions: North America, Europe, Innovative Features & submission est. December 2025 Asia-Pac, Latin America, ME&A Benefits • MoA – New mode of action • Safety - Im
Slide 12: Flying & Crawling Insects: A Large Commercial Opportunity
Flying & Crawling Insects: A Large Commercial Opportunity Professional vector control market is approximately A$840M p.a.1 In 2020, the regional split by sales volume and value was: The Global mosquito control market size is projected to grow by Sales (%): Value (US$M) 38% between 2021 and 2026.1 #1
Slide 13: Flavocide for Use As a Stored Grain Protectant
Flavocide® for Use As a Stored Grain Protectant Infested grain is not acceptable. The tolerance for live storage pests in grain sold off-farm either for Zero Tolerance the domestic, human consumption market or for the export Pest (Scientific name) Resistance (Chemical class) market is nil. Flat grai
Slide 14: Flavocide for Use As a Stored Grain Protectant
Flavocide® for Use As a Stored Grain Protectant A potential new option to protect against resistant insects. Bio-Gene has to date undertaken significant research on the Damage to grain during storage due to potential to develop and commercialise Flavocide as a stored grain infestation leads to signi
Slide 15: Qcide - a Natural Product for Consumer Use
Qcide ® - a Natural Product for Consumer Use For flying, crawling and sucking pests in the home and garden. Consumer Segments Global Consumer Opportunity Current Solutions & Suppliers Unmet Needs • Garden: • Consumer Drivers: • Current Consumer Products: • Changing Consumer Lawn care, ornamentals,
Slide 16: Qcide - a Natural Product for Consumer Use
Qcide ® - a Natural Product for Consumer Use For flying, crawling and sucking pests in the home and garden. A Range of Products • Qcide may be used alone or in combination and in a range of formulation types, to target multiple pests in several key use areas. • May be formulated to target specific i
Slide 17: Bio-Gene's Strategic Priorities
Bio-Gene’s Strategic Priorities Speed Focused Product Commercial Efficient Use particularly the pre-registration Development Validation of Capital manufacturing and safety studies for Flavocide and Qcide active to deploy our resources against a to build on existing commercial to leverage the funding
Slide 18: Bio-Gene's Board and Management Team
Bio-Gene’s Board and Management Team Strong experience in new product development and international partnering. Alex Ding Tim Grogan Andrew Guthrie Peter May Chris Ramsey Chairman MD & CEO Non-Executive Director Executive Director R&D Non-Executive Director Previously partner at two law 32 years exp
Slide 19: Bio-Gene - Key Corporate Metrics
Bio-Gene – Key Corporate Metrics Corporate Fundamentals Market Capitalisation Approx A$ 10.9M Listing ASX:BGT Shares on issue 201,361,570 Average Daily Trading 60.823 Financial Position Cash Balance (30 Sep 23) A$ 3.48 million Runway: Q2 CY2024 Cash at end of period 5,81 7,23 6,34 5,26 4,26 3,58 2,9
Slide 20: Bio-Gene Investment Proposition
Bio-Gene Investment Proposition Key Expectations for CY 2024 & 2025 Flavocide AI & Qcide AI – data for regulatory filing (est. December 2025 for Flavocide) New & expanded partnering (both Flavocide & Qcide) Medium and Long-Term Factors Supporting Sustained Value Creation Strong industry need for new
Slide 21: Bio-Gene Technology Limited
Developing New Insecticides Derived From Nature to Achieve High Impact - Globally Bio-Gene Technology Limited ASX:BGT bgt.info@bio-gene.com.au www.bio-gene.com.au Registered Office Level 6 400 Collins Street Melbourne, Victoria, 3000 AUSTRALIA 21
Bio-Gene Technology — Investor Presentation (December 2023) on 6ix